HALO HALOZYME THERAPEUTICS, INC.

NEUTRAL Impact: 2/10 Insider Cluster (2 insiders)
Horizon immediate Filed Jun 4, 2026 Processed 11d 8h ago
Insider cluster: 2 insiders, $214K total
Latest settled — T+1d
HALO ▼ -0.10% at T+1d
NEUTRAL call ✗ call lost -0.10% · α vs SPY +2.50% · entry $71.60 → $71.53
Next anchor: T+5d due 5d ago
Last close $69.50 (close Jun 12) · -2.93% from $71.60 entry
Entry anchored
Jun 3, 2026
via day open
T+1d
-0.10%
call -0.10% · α +2.50%
$71.53
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

CEO Helen Torley and a director sold a combined ~$214K in open-market shares on June 1, 2026, at ~$66/share. The CEO also exercised options at $12.07 and sold a portion of the resulting shares in a same-day same-window pattern, which is typical for tax-covering and liquidity rather than a bearish signal. The total open-market sales represent ~0.003% of HALO's $7.9B market cap — trivial and routine.

Key Financial Metrics

Direction
selling
Total Value
$214.0K
Insiders
2

Actionable Insight

This insider cluster is routine and non-informative. The CEO's option exercises and same-day sales are standard cashless exercise mechanics, not a bearish signal. No action warranted; monitor for any material corporate events that could trigger more substantial insider activity.

Key Facts

  • CEO Helen Torley sold 1,610 shares open-market on June 1, 2026, for ~$107K.
  • Director Bernadette Connaughton sold 1,625 shares open-market on June 1, 2026, for ~$108K.
  • CEO also exercised 70,000 options at $12.07 on June 1-3, 2026, and sold a portion of the resulting shares — a routine cashless exercise pattern.
  • Total open-market sales of ~$214K represent ~0.003% of HALO's $7.9B market cap — immaterial.
  • No other insiders traded in the window; the cluster is limited to two individuals.

Financial Impact

Total open-market sales of ~$214K, or ~0.003% of market cap.

Risk Factors

  • None from this filing — the cluster is too small to be informative.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (16 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-HALO-1780531645955
3 reports for HALO
Performance horizon
Filters
Rows
Reports for HALO — sortable, filterable
Type Now
Jun 4, 2026
11d ago
Insider Cluster
NEUTRAL ★ 2/10
$71.60 $71.53▼ −0.10%▲ +2.50%$69.50 (−2.93%)
Apr 30, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$63.66 $63.96▲ +0.47%▲ +0.25%$69.50 (+9.17%)
Mar 23, 2026
11w ago
DEFA14A
NEUTRAL ★ 2/10
$62.04 $63.24▲ +1.93%▲ +1.37%$69.50 (+12.02%)
Showing 3 of 3

US Market Status

Market Closed — Opens in 4h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access